Eton Secures U.S. Rights for Anaphylm; PDUFA Date Set for March 2027
What happened
Eton received exclusive U.S. commercialization rights for Anaphylm, which was tied to FDA acceptance. The FDA accepted the resubmitted New Drug Application as a Class 2 response, setting the Anaphylm PDUFA Date for March 16, 2027. Eton also received a $10 million upfront payment for these exclusive U.S. commercialization rights.
From fool.com
Why it matters
The FDA's acceptance of the resubmitted application advances the timeline for Anaphylm's market availability. The $10 million upfront payment provides immediate capital to Eton, while the company maintained its full-year revenue guidance of $46 million to $50 million for the 2026 fiscal year.
From fool.com
Who's involved
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- CDER faces March 2027 deadline for Anaphylm drug reviewCDER faces a critical March 2027 deadline for Anaphylm drug reviewLikely
- How could Eton securing commercialization rights affect Daniel Barber's company?Eton's exclusive U.S. rights could secure major funding and commercial launch for AnaphylmLikely
- Congress may face increased legislative focus following Anaphylm's FDA milestoneCongress may face increased legislative focus following Anaphylm's FDA milestonePossible
Keep exploring
The entities involved
Related events
- Medical societies and AAP challenge FDA guidance on e-cigarettes, while Congress grants FDA authority to regulate tobacco.
- FDA removed the clinical hold on Arbutus Biopharma Corporation's IND application, allowing potential clinical development.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- Litigation regarding FDA approval process.